Blog

Drew Moghanaki: GO2 for Lung Cancer ensuring access to high-quality lung cancer screening for Veterans at risk

Photo from prnewswire.com

Jul 25, 2024, 01:13

Drew Moghanaki: GO2 for Lung Cancer ensuring access to high-quality lung cancer screening for Veterans at risk

Drew Moghanaki shared a post on X:

“Thank you, GO2 for Lung Cancer for your decades-long efforts with Congress and the VA to ensure access to high-quality lung cancer screening for Veterans at risk.”

Source: Drew Moghanaki/X

Dr. Drew Moghanaki is a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.

He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).

cancer Congress Drew Moghanaki GO2 for Lung Cancer Laurie Fenton Ambrose Lung cancer lung cancer screening OncoDaily Oncology Veteran awareness Veterans Health Administration VHA

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage